This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Cyclosporin A, a recently developed experimental immunosuppressant drug that appears to prevent or delay rejection of kidney and other transplants, may also be effective against an eye disease responsible for 10% of all visual impairment in the United States.
The disease, which has several subgroups, is called posterior uveitis. It has been successfully treated in animals with cyclosporin A, and patients now are being recruited for a clinical trial of the drug at the National Institutes of Health in Bethesda, Md.
In posterior uveitis, tissues of the uvea and the retina become inflamed. The disease may be fairly abrupt in onset and is often characterized initially by "floaters" and cloudy or hazy vision. Severe or repeated inflammation will damage the retina and, left untreated, the disease eventually may cause blindness. Corticosteroids and other immunosuppressants currently used to control the disorder have the usual drawbacks and, in addition, are not always
Cyclosporin A for posterior uveitis? JAMA. 1982;247(5):569. doi:10.1001/jama.1982.03320300003001
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: